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Histone 3.3 hotspot mutations 
in conventional osteosarcomas: a 
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characterization of six H3F3A mutated cases
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Abstract 
Background: Histone 3.3 (H3.3) hotspot mutations in bone tumors occur in the vast majority of giant cell tumors of 
bone (GCTBs; 96%), chondroblastomas (95%) and in a few cases of osteosarcomas. However, clinical presentation, his‑
topathological features, and additional molecular characteristics of H3.3 mutant osteosarcomas are largely unknown.
Methods: In this multicentre, retrospective study, a total of 106 conventional high‑grade osteosarcomas, across all 
age groups were re‑examined for hotspot mutations in the H3.3 coding genes H3F3A and H3F3B. H3.3 mutant osteo‑
sarcomas were re‑evaluated in a multidisciplinary manner and analyzed for genome‑wide DNA‑methylation patterns 
and DNA copy number aberrations alongside H3.3 wild‑type osteosarcomas and H3F3A G34W/L mutant GCTBs.
Results: Six osteosarcomas (6/106) carried H3F3A hotspot mutations. No mutations were found in H3F3B. All patients 
with H3F3A mutant osteosarcoma were older than 30 years with a median age of 65 years. Copy number aberra‑
tions that are commonly encountered in high‑grade osteosarcomas also occurred in H3F3A mutant osteosarcomas. 
Unlike a single osteosarcoma with a H3F3A K27M mutation, the DNA methylation profiles of H3F3A G34W/R mutant 
osteosarcomas were clearly different from H3.3 wild‑type osteosarcomas, but more closely related to GCTBs. The most 
differentially methylated promoters between H3F3A G34W/R mutant and H3.3 wild‑type osteosarcomas were in KLLN/
PTEN (p < 0.00005) and HIST1H2BB (p < 0.0005).
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Background
Osteosarcoma is a malignant bone forming neoplasm 
with a broad spectrum of morphologies [1]. Conventional 
high-grade osteosarcoma is the most common subtype 
and typically arises in the long bones of the extremities 
with a predilection to the metaphysis, although any bone 
of the skeleton may be affected. The incidence of osteo-
sarcomas has a bimodal age distribution with a first peak 
in the second decade of life and a second smaller peak in 
older adults [1, 2].
The etiology of osteosarcomas is still largely unknown. 
However, several genetic syndromes (e.g. Li-Fraumeni 
and hereditary retinoblastoma) greatly increase the 
risk of developing osteosarcomas, especially in younger 
patients [3, 4]. Osteosarcomas in older patients often 
develop from a precursor bone lesion that is prone for 
malignant transformation (i.e. Paget disease) or may 
occur after radiation treatment for other diseases, typi-
cally after a latency period of several years [1, 5, 6].
The genomic landscape of osteosarcomas is com-
plex [7]. A remarkable attribute of primary and second-
ary conventional osteosarcomas is their chromosomal 
instability leading to high aneuploidy [8]. Chromosomal 
regions frequently affected by somatic structural vari-
ations and copy number alterations often contain cell-
cycle regulating genes such as TP53, RB1, or c-MYC [9, 
10]. Sequencing studies revealed recurrent mutations 
affecting these genes, supporting their major role in 
osteosarcoma development [8]. However, the mutational 
make-up of osteosarcomas is versatile, as some osteosar-
comas also present with molecular signatures reminis-
cent of BRCA1/2 deficient tumors [10]. Chromothripsis, 
a single cellular catastrophic event resulting in extensive 
DNA rearrangements and DNA copy number changes, 
has been observed in roughly one-third of osteosarcomas 
[11].
Alternative lengthening of telomeres (ALT), a tel-
omere maintaining mechanism compensating progres-
sive telomere attrition by homologous recombination 
of telomere sequences, is associated with chromosomal 
instability in osteosarcomas [12]. Almost all osteosarco-
mas utilize ALT, highlighting its particular importance 
in these tumors [8, 13]. Somatic mutations in the H3.3-
ATRX-DAXX chromatin-remodeling pathway have been 
linked to ALT in different tumor entities [14, 15]. ATRX 
(α-thalassaemia/mental retardation syndrome X-linked) 
mutations, which result in a loss of its nuclear expression, 
were found in osteosarcomas at a frequency of 20–30% 
[8, 16]. Loss of DAXX (death-domain associated protein) 
expression has not yet been observed in any sarcoma 
[17]. However, a high frequency of mutations in the two 
genes encoding histone 3 variant 3 (H3.3) was revealed in 
certain bone tumors. Giant cell tumors of bone (GCTBs) 
almost always carry mutations in H3F3A at codon 34, 
whereas chondroblastomas are characterized by a high 
frequency of H3F3B mutations at codon 36 [18–20]. Lit-
tle is known about H3.3 mutations in osteosarcomas. 
Previous studies described single high-grade osteosarco-
mas carrying H3.3 mutations, whereas other series did 
not. So the question arises whether osteosarcomas carry-
ing H3.3 mutations really exist or might rather be malig-
nant variants of GCTBs [8, 18–21].
The present study addresses these issues by determin-
ing the frequency of H3.3 mutations across the entire 
age spectrum in de novo high-grade osteosarcomas of 
the conventional type. Genome-wide DNA methylation 
and DNA copy number profiling was applied to gain fur-
ther molecular insight into osteosarcomas carrying H3.3 
mutations.
Methods
Tissues specimens
Tissue samples of 106 de novo high-grade osteosarcomas 
of the conventional type (86 primary tumors, 3 recur-
rences, 17 metastases) and 14 GCTBs, one of them with 
signs of malignancy in the local relapse two  years after 
surgical treatment, serving as H3.3 G34 mutant bone 
tumor control group were collected from the Institutes 
of Pathology of the University Hospital Heidelberg, 
Cologne, Jena (Germany), and Nijemegen (the Neth-
erlands). Patients’ characteristics are outlined in Addi-
tional file  1: Table S1. Tissue samples were banked in 
the archives of the Department of Pathology and admin-
istered by the tissue bank of the National Center for 
Tumor Diseases (NCT), Heidelberg. Initial diagnoses 
were established by interdisciplinary oncology boards 
and were based on radiological findings, standard histo-
pathological criteria in conjunction with immunohisto-
chemical and molecular analyses according to the current 
WHO classification [1]. H3.3 mutant osteosarcomas were 
Conclusions: H3.3 mutations in osteosarcomas may occur in H3F3A at mutational hotspots. They are overall rare, but 
become more frequent in osteosarcoma patients older than 30 years. Osteosarcomas carrying H3F3A G34W/R muta‑
tions are associated with epigenetic dysregulation of KLLN/PTEN and HIST1H2BB.
Keywords: Mutation, H3.3, H3F3A, HIST1H2BB, KLLN, PTEN, Osteosarcoma, Giant cell tumor of bone, DNA 
methylation, Copy number alteration
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correlated with clinical information and were histologi-
cally and radiologically re-evaluated where available. The 
local ethics committee approved these analyses.
DNA extraction and Sanger sequencing of H3F3A/B 
mutational hotspots
Source material for DNA extraction was formalin-fixed 
and paraffin-embedded (FFPE) tumor tissue. Representa-
tive tumor tissue with highest available tumor content 
was chosen for genomic DNA isolation, as microscopi-
cally documented on H&E stained paraffin sections. 
In GCTBs, which are known for their prominent non-
tumoral giant cell component, areas with predominant 
tumor cells (at least 70%) were selected for DNA extrac-
tion. The  Maxwell® 16FFPE Plus LEV DNA Kit was 
applied on the automated Maxwell device (Promega, 
Madison, WI, USA) according to the manufacturer’s 
instructions. Polymerase chain reaction was performed 
with 20  ng of DNA under conditions as previously 
described [19]. Two microliters of the amplification prod-
uct were submitted to bidirectional sequencing using the 
BigDye Terminator v3.1 Sequencing Kit (Applied Biosys-
tems, Foster City, CA, USA). Sequences were determined 
using an ABI 3500 Genetic Analyzer (Applied Biosys-
tems) and the Sequence Pilot version 3.1 (JSI-Medisys, 
Kippenheim, Germany) software.
Genome‑wide DNA methylation data generation 
and pre‑processing
The Illumina Infinium HumanMethylation450 (450  k) 
array was used to assess the DNA methylation status of 
482,421 CpG sites (Illumina, San Diego, USA), according 
to the manufacturer’s instructions at the Genomics and 
Proteomics Core Facility of the German Cancer Research 
Center (DKFZ) Heidelberg. DNA methylation data were 
normalized by performing background correction and 
dye bias correction (shifting of negative control probe 
mean intensity to zero and scaling of normalization con-
trol probe mean intensity to 10,000, respectively). Probes 
targeting sex chromosomes, probes containing multiple 
single nucleotide polymorphism and those that could 
not be uniquely mapped were removed. In total, 438,370 
probes were kept for analysis.
Unsupervised clustering, copy number profiling 
and identification of differentially methylated regions
For unsupervised hierarchical clustering, we selected 
20,000 probes that showed the highest standard devia-
tion (SD) of beta values across the entire dataset. Samples 
were hierarchically clustered using the 1-Pearson correla-
tion coefficient as distance measure and average linkage. 
DNA methylation probes were reordered using Euclidian 
distance and complete linkage.
Copy number profiles were generated from the 450  k 
raw data using the ‘conumee’ R package and assessed 
manually. The dmpFinder method of the R package minfi 
was used for the identification of differentially methyl-
ated regions [22]. Both packages are available from the 
Bioconductor repository (http://www.bioconductor.org).
Statistical analysis
A two-sided t test was used to test for differences 
between the mean values for continuous variables. P val-
ues of less than 0.05 were considered significant.
Results
H3F3A mutations occur in high‑grade osteosarcomas 
of elderly patients
Targeted sequencing of the two genes encoding histone 3 
variant 3 (H3F3A and H3F3B) in 106 de novo high-grade 
osteosarcomas revealed six H3F3A mutant cases (Fig. 1a). 
One case carried a c.80A>T heterozygous mutation lead-
ing to an amino acid exchange of lysine by methionine at 
codon 27 (K27M). Another osteosarcoma presented with 
a c.100G>C heterozygous mutation leading to an exchange 
of glycin (G) by arginine (R) at codon 34. Four cases car-
ried a c.100G>T mutation, one hemizygous and three 
heterozygous, leading to an exchange of glycin (G) by tryp-
tophan (W). No mutation was detected in H3F3B. Patients 
with H3F3A mutant osteosarcomas were diagnosed at 
higher age (median age 65  years; range 34–75  years vs 
median age 18  years; range 2–86  years) and were sig-
nificantly older (p < 0.05) compared to the control group 
of H3F3A mutant GCTBs (median age 29  years, range 
18–75  years). Hence, the incidence increased from over-
all 5% (6/106) to 15% (6/40) in osteosarcoma patients over 
30 years of age (Fig. 1b, c). The six H3F3A mutant osteo-
sarcomas affected the long bones and were distributed 
similar to H3.3 wild-type osteosarcomas and GCTBs. They 
occurred in the proximal and distal femur, proximal tibia, 
proximal fibula, or the distal radius (Fig. 1c; Table 1).
Radiological features and histological patterns are 
indistinguishable between H3F3A mutant and H3.3 
wild‑type osteosarcomas
Radiological data was available for re-evaluation in five of 
six H3F3A mutant osteosarcomas (Fig. 2; Additional file 2: 
Figure S1). At radiographic examination, the tumors to a 
variable extent demonstrated a mixed pattern of sclerotic 
opacities with mineralization and lytic areas violating the 
cortex. The infiltrative growth pattern was associated with 
expansive growth into the surrounding soft tissue. Some 
cases presented with prominent soft-tissue masses (e.g. 
Fig.  2b). On MR imaging, where available, these masses 
partly wrapped around the circumference of the affected 
bone (Additional file 2: Figure S1).
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All six H3F3A mutant cases showed histological fea-
tures indistinguishable from other conventional high-
grade osteosarcomas (Fig. 2; Additional file 3: Figure S2). 
Mitotic activity was variable with presence of atypical 
mitotic figures. Neoplastic bone formation was observed 
in all H3F3A mutant osteosarcoma, although to a vari-
able extent. Of note, giant cells were sparse to absent in 
all six H3F3A mutant osteosarcomas.
DNA methylation profiling separates H3F3A G34 mutant 
osteosarcomas from H3.3 wild‑type counterparts
We next investigated the six H3F3A mutant and 28 H3.3 
wild-type osteosarcomas and 14 H3F3A G34W/L mutant 
GCTBs for genome-wide DNA methylation patterns 
applying the 450 k DNA methylation array (Fig. 3). Unsu-
pervised hierarchical clustering identified two distinct 
DNA methylation clusters (Fig. 3, upper panel). The first 
cluster was composed of H3.3 wild-type osteosarcomas 
and the single osteosarcoma carrying a H3F3A K27M 
mutation. This particular case was indistinguishable 
from that of H3.3 wild-type osteosarcomas. The second 
methylation cluster was composed of the five H3F3A 
G34 mutant osteosarcomas and the H3F3A G34 mutant 
GCTB control cases. Within this cluster, the 14 GCTBs 
showed the most homogeneous DNA methylation pat-
terns and accordingly grouped together (Fig. 3, heatmap 
with dendrogram).
We next analyzed copy number data derived from the 
DNA methylation arrays (Fig.  3, lower panel). H3F3A 
mutant osteosarcomas frequently showed a gain of chro-
mosome arm 8q involving the c-MYC locus (3/6) and 
a distinct deletion of 3q13.31 involving LSAMP (2/6). 
However, c-MYC amplification, 6p12–21 amplification or 
chromothripsis, both hallmark copy number alterations 
in osteosarcomas, were absent in all six H3F3A mutant 
osteosarcomas. GCTBs lacked any copy number altera-
tions except for the single GCTB with a secondary malig-
nant transformation (Additional file 4: Figure S3).
H3F3A G34 mutant osteosarcomas present with a 
promoter methylation phenotype
Given the distinct DNA methylation patterns of H3F3A 
G34 mutated osteosarcomas we next examined differ-
ences in DNA methylation in specific genomic regions 
(Fig. 4). H3F3A G34 mutant and H3.3 wild-type osteo-
sarcomas showed widespread hypomethylation across 
the whole genome, especially in non-promoter regions, 
which was particularly prominent at centromeres and 
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telomeres (Fig.  4a). However, H3F3A G34 mutant 
osteosarcomas had higher methylation levels in pro-
moter regions compared with their H3.3 wild-type 
counterparts. Specifically, we found that the promoter 
region of the genes HIST1H2BB (p  <  0.00005) and 
KLLN/PTEN (p  <  0.0005) showed significantly higher 
methylation levels in H3F3A G34 mutant osteosarco-
mas (Fig. 4b).
Discussion
H3.3 mutations in bone tumors occur with an exceed-
ingly high frequency in GCTBs and chondroblastomas 
[18, 19]. We herein present for the first time a clinical and 
molecular characterization of six H3F3A mutant de novo 
osteosarcomas and suggest that H3.3 mutations might 
define a distinct molecular subtype in the heterogeneous 
group of osteosarcomas.
Looking at the H3F3A G34 mutational status and the 
age distribution alone raises the possibility that the 
group of H3.3 mutant osteosarcomas may be composed 
of GCTBs presenting with Denosumab-therapy induced 
changes mimicking an osteosarcoma-like histology, may 
have undergone malignant progression or may represent 
the very rare de novo malignant variant of GCTBs, the 
latter two of which are known for their occurrence in 
elderly [23–25]. It is also evident that osteosarcomas in 
elderly are often of secondary origin, which would fur-
ther argue in this direction [1].
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Fig. 2 Radiologic appearance and morphological phenotypes of H3F3A mutant osteosarcomas. a Anteroposterior radiograph of the left wrist 
shows a lesion in the epi‑ and metaphysis of the distal radius (left). Histology revealed an osteoblastic osteosarcoma with pronounced nuclear 
atypia, brisk mitotic activity and a compact, extensive sclerosing osteoid matrix. b Lateral radiograph of the right knee shows a lesion in the distal 
femoral metaphysis with infiltration of the epiphysis and prominent extension into the soft tissue. The tumor was composed of pleomorphic, rela‑
tively plump and focally spindle‑shaped tumor cells depositing osteoid in plaques (mixed osteoblastic/fibroblastic osteosarcoma). c Lateral radio‑
graph of the right knee shows a lesion in the distal femoral meta‑ and epiphysis with subchondral extension and infiltration of the joint. The tumor 
(mixed osteoblastic/fibroblastic osteosarcoma) was predominantly composed of plump tumor cells producing coarse plaque‑like osteoid. d Lateral 
radiograph of the right knee shows a lesion in the proximal fibula (caput fibulae). Histology revealed an osteoblastic osteosarcoma with highly 
pleomorphic tumor cells focally producing coarse and lace‑like osteoid deposits. e Anteroposterior radiograph of the hip joint shows a lesion in 
the intertrochanter and subtrochanter region of the proximal femur. Histology revealed a mixed osteoblastic/fibroblastic osteosarcoma with coarse 
osteoid production. f X‑ray imaging of the proximal tibia was not available in case 79,428. Histologically this bone lesion presented as osteosarcoma 
(mixed osteoblastic/fibroblastic subtype) with neoplastic bone production that was focally arranged in a coarse lace‑like pattern. Foci with necrosis 
and dystrophic calcification were noted. White arrows indicate the corresponding lesion (a–e). Scale bars equal 50 µm (a–f)
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Indeed, at least for the H3F3A G34 mutant osteosar-
coma cases presented here, there is no absolute certainty 
that they might not represent the most undifferentiated 
end in a spectrum of GCTB differentiation. However, 
none of the H3F3A mutant osteosarcomas presented 
with distinct radiological and histological features resem-
bling GCTBs or its malignant variant, even though the 
radiologic appearance of malignant GCTBs may be 
challenging to distinguish from osteosarcomas [26]. We 
also cannot preclude with absolute certainty that areas 
reminiscent for a GCTB were missed due to a sam-
pling bias in the H3F3A mutant osteosarcomas, which 
would argue for the extremely rare de novo malignant 
variant of GCTBs. However, this can be considered very 
unlikely. Furthermore, the patients were treated accord-
ing to standard treatment protocols for osteosarcoma, 
thereby excluding Denosumab-induced changes. It is also 
unlikely that a precursor lesion underwent malignant 
transformation, since medical records were empty in this 
regard (Table  1). Therefore, taking all information into 
account, the diagnosis conventional osteosarcoma has 
been retained in all six H3.3 mutant cases. The H3F3A 
mutant osteosarcoma cases of this study predominantly 
occurred at higher patient age. This finding might explain 
why other osteosarcoma studies focusing on pediat-
ric patients alone did not find H3.3 mutations at all [8]. 
However, larger future studies will be required to con-
firm that H3F3A mutant osteosarcomas are rare or even 
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absent in children and adolescent patients. Interestingly, 
the age distribution of the H3.3 mutant osteosarcomas is 
in contrast to H3.3 mutant brain tumors, which typically 
present at younger age than their wild-type adult coun-
terparts [15, 27]. This observation coupled with evidence 
from studies about H3F3A G34 mutant GCTBs might 
suggest an entity dependent age distribution of H3.3 
mutant tumors [18, 19].
Our integrated approach revealed several molecu-
lar alterations in H3F3A mutant osteosarcomas that are 
typical for high-grade osteosarcomas. A homozygous 
deletion of 3q13.31 carrying the LSAMP gene was seen 
in two of the six H3F3A mutant osteosarcomas. One of 
them additionally carried a TP53 deletion, a prominent 
tumor suppressor gene known to be involved in the 
development of osteosarcomas [8]. LSAMP is a tumor 
suppressor that is frequently inactivated in conven-
tional osteosarcomas and linked to increased prolifera-
tion. It is also a predictor for an unfavorable biological 
behavior [28]. Thus, an aggressive biological behavior 
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typically seen in conventional osteosarcomas might also 
be assumed for osteosarcomas with H3F3A mutations. 
Accordingly, three of four H3F3A mutant osteosarcoma 
patients with follow-up data available showed an unfa-
vorable clinical course. Two patients died of the disease 
shortly after diagnosis. One patient presented with wide-
spread metastases and progressive disease (Table 1).
A gain of chromosome 8q bearing the c-MYC locus was 
detected in three of six H3F3A mutant osteosarcomas. 
Amplification of c-MYC, a member of the MYC transcrip-
tion factor family tightly involved in the modulation of gene 
expression and a strong oncogene, has been frequently 
observed in osteosarcomas [7, 8, 10]. It has also been 
shown in mice that c-MYC overexpression in mesenchymal 
bone stem cells may induce osteosarcomas [29]. The gain 
of 8q might confer a tumor propagating gene dosage effect, 
although c-MYC is not amplified in the six H3F3A mutant 
osteosarcomas presented here. In this context, other MYC 
gene family members may also be pivotal in the develop-
ment of H3F3A mutant osteosarcomas. Brain tumors 
with H3F3A G34 mutations have been associated with 
an increased expression of MYCN, another transcription 
factor well known for its oncogenic capacity [30]. Expres-
sion analysis might give further insights whether c-MYC, 
MYCN, and/or other oncogenes orchestrate together in 
H3F3A G34 mutant osteosarcomas. The H3F3A G34 muta-
tion alone will probably not be sufficient to induce osteo-
sarcomas, since GCTBs carrying such mutations usually do 
not undergo malignant transformation [1].
We also detected one osteosarcoma with a H3F3A 
K27M mutation. This mutation was initially found in 
diffuse pontine midline gliomas and has recently been 
described also in other brain tumor entities [27, 31]. The 
H3F3A K27M mutation has been demonstrated lead-
ing to an enzymatic inhibition of EZH2 in brain tumors, 
a catalytic subunit of Polycomb Repressor Complex 2 
[32]. EZH2 catalyzes methylation of histone H3 at lysine 
27 and mediates gene silencing of target genes via local 
chromatin reorganization. Dysregulated EZH2 activity is 
seen in many cancer types [33]. We here report the first 
H3 K27M mutant tumor outside the nervous system. It 
therefore remains to be determined whether the under-
lying molecular mechanisms of H3.3 K27M mutation 
described in brain tumors may be adapted to other can-
cer types.
Interestingly, the DNA methylation analysis revealed 
several differing aspects in H3F3A mutant osteosarco-
mas compared to their H3.3 wild-type counterparts. 
Our data indicate that the DNA methylation signa-
ture of G34 mutant osteosarcomas is different to their 
conventional wild-type counterparts, but more closely 
related to GCTBs. However, this difference was only seen 
for G34 mutant cases, since the single K27M mutant 
osteosarcoma of this series was indistinguishable from 
H3.3 wild-type cases. On the one hand, the close rela-
tion between H3F3A G34 mutant osteosarcomas and 
H3F3A G34W/L mutant GCTBs might suggest a similar 
cell of origin. On the other hand, their close relation at 
the methylation level might reflect similar changes in the 
epigenetic landscape caused by the H3F3A G34 muta-
tion or a responsible higher order mechanism. However, 
the DNA methylation profile of a dedifferentiated chon-
drosarcoma, in which we detected a H3F3A G34L muta-
tion, was neither related to GCTBs, nor related to H3F3A 
G34W/R mutant osteosarcomas (data not shown).
In-depth analysis of the methylome data revealed 
widespread DNA hypomethylation in both, H3F3A G34 
mutant and wild-type osteosarcomas. DNA hypometh-
ylation is generally more pronounced with increased 
aggressiveness, which might explain this pattern [34]. 
However, the hypomethylation phenotype was less pro-
nounced within the promoter regions in H3F3A G34 
mutant osteosarcomas compared to their wild-type 
counterparts. The most differentially methylated pro-
moter regions involved the HIST1H2BB and KLNN/
PTEN genes. Both showed significantly higher methyla-
tion in H3F3A G34 mutant osteosarcomas. The role of 
HIST1H2BB in cancer is largely unknown. HIST1H2BB 
is an integral element of the nucleosome complex and 
hence, impaired expression could disrupt the physi-
ological status and affect nucleosome remodelling [35]. 
KLNN is located juxtaposed to PTEN on chromosome 
10q23 and both genes share the same promoter site [36]. 
Accordingly, both genes probably might be affected in 
H3F3A G34 mutant osteosarcomas. An important role 
of PTEN in the development of osteosarcomas has not 
been described yet, although PTEN alteration has been 
observed [8, 10, 37]. The neighboring gene KLLN func-
tions at the pericentric region of chromosomes. KLLN 
organizes the heterochromatin by maintaining the H3K9 
trimethylation and thereby contributes to chromosomal 
stability. Loss of KLLN resulted in the dysregulation of 
pericentric heterochromatin with consequent chromo-
somal instability and numerical chromosomal aberra-
tions in  vitro [38]. Interestingly, hypomethylation was 
significantly pronounced around the pericentric region 
in H3F3A G34 mutant osteosarcomas compared with 
GCTBs. Whether the hypomethylation phenotype may 
be a surrogate for pericentric instability and the role of 
KLLN in context of H3.3 mutations will be subject of 
future projects.
Conclusions
Taken together, our data confirm that detection of H3F3A 
mutations in bone tumors does not exclude malignancy 
in individual cases, especially in older patients. H3F3A 
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mutant conventional high-grade osteosarcomas may 
radiologically, histologically and karyotypically be indis-
tinguishable from conventional high-grade osteosarco-
mas, but present with distinct epigenetic features.
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